New blade design for pars plana vitrectomy: A quantum leap

Article

In this article, the authors present the highlights of their research into a new blade design for pars plana vitrectomy.

In fact, the blade progressively obstructs the entire cutting port at every cutting action, zeroing flow at the end of each cutting cycle. The variability of open port surface generates flow instability and continuous fluid acceleration and deceleration, leading to limited efficiency and retinal traction.1

We have been studying the fluidics of guillotine blade vitreous cutters by means of a technique named 'particle image velocimetry',1 showing that both Venturi and peristaltic pump equipped instruments determine macroscopic fluid acceleration which, in turn, results in retinal traction. The road towards a safer removal of the vitreous jelly passes through a better comprehension of its fluidics and the goal is to reduce drastically fluid velocity changes.

To partially overcome this problem, most available machines are used at increasingly higher aspiration values, as cut rate increases, because this is virtually the only way to aspirate enough vitreous through the port within the shorter available time window.

Available pneumatic valves, used to close the blade (and in some vitrectomy machines, also to open it up), take 0.03 seconds, while strains used to open the port need a little more time: 0.07 seconds. This time is 'incompressible', so that when cut rate is increased, this is done at the expense of 'open port' time because 'port opening' and 'port closing' times remain fixed and can not really be modified for technical reasons while the 'closed port' time is set to zero at higher cut rates.

Overall, opening and closing the blade takes between 6 and 10 thousands of a second, so if we make the 'closed port' time zero seconds, the theoretical maximum cut rate per minute with available valves is between 6000 (= 60 s/0.01 s) and 8571 (= 60 s/0.007).

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
At EURETINA 2024, Martin S. Zinkernagel, MD, PhD, on the future of real-world AI use
Alexandra Miere, MD, PhD, Associate Professor of Ophthalmology, University Paris Est Créteil, France, speaks at EURETINA
Veeral S. Sheth, MD, MBA, FASRS, FACS, discussed the outcome of the Phase 1 HELIOS trial of OTX-TKI at from this year's EURETINA congress being held in Barcelona, Spain, which takes place September 19-22, 2024.
© 2024 MJH Life Sciences

All rights reserved.